NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Cantor A, Bougatsos C, et al. Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov. (Evidence Syntheses, No. 96.)

Cover of Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation

Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet].

Show details

REFERENCES

1.
Chou R, Smits AK, Huffman LH, Fu R, Korthuis PT. Prenatal screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143(1):38–54. [PubMed: 15998754]
2.
Chou R, Smits AK, Huffman LH, Korthuis PT. Screening for Human Immunodeficiency Virus in Pregnant Women, Evidence Synthesis No. 39. Rockville, MD: Agency for Healthcare Reseach and Quality; 2005. [8 November 2012]. Accessed at http://www​.ncbi.nlm.nih​.gov/books/NBK33383/ on.
3.
U.S. Preventive Services Task Force. Screening for HIV: recommendation statement. Ann Intern Med. 2005;143(1):32–7. [PubMed: 15998753]
4.
Centers for Disease Control and Prevention. HIV-2 infection surveillance—United States: 1987–2009. MMWR Morb Mortal Wkly Rep. 2011;60(29):985–8. [PubMed: 21796096]
5.
Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1–19. [PubMed: 1361652]
6.
Centers for Disease Control and Prevention. HIV Among Women. Atlanta: Centers for Disease Control and Prevention; 2011. [8 November 2012]. Accessed at http://www​.cdc.gov/hiv​/topics/women/pdf/women.pdf on.
7.
Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. MMWR Morb Mortal Wkly Rep. 2011;60(21):689–93. [PubMed: 21637182]
8.
Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2009. Atlanta: Centers for Disease Control and Prevention; 2011. [8 November 2012]. Accessed at http://www​.cdc.gov/hiv​/surveillance/resources​/reports/2009report/ on.
9.
Centers for Disease Control and Prevention. STDs & Pregnancy: CDC Fact Sheet. Atlanta: Centers for Disease Control and Prevention; 2012. [8 November 2012]. Accessed at http://www​.cdc.gov/std​/pregnancy/STDfact-Pregnancy.htm on.
10.
Centers for Disease Control and Prevention. HIV Surveillance Supplemental Report: Enhanced Perinatal Surveillance—15 Areas, 2005–2008. Atlanta: Centers for Disease Control and Prevention; 2011. [8 November 2012]. Accessed at http://www​.cdc.gov/hiv​/surveillance/resources​/reports/2010supp_vol16no2/index​.htm on.
11.
Centers for Disease Control and Prevention. Achievements in public health: reduction in perinatal transmission of HIV infection—United States, 1985–2005. MMWR Morb Mortal Wkly Rep. 2006;55(21):592–7. [PubMed: 16741495]
12.
Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2010. Atlanta: Centers for Disease Control and Prevention; 2012. [8 November 2012]. Accessed at http://www​.cdc.gov/hiv​/surveillance/resources​/reports/2010report/index.htm.
13.
Fowler MG, Gable AR, Lampe MA, Etima M, Owor M. Perinatal HIV and its prevention: progress toward an HIV-free generation. Clin Perinatol. 2010;37(4):699–719. [PubMed: 21078445]
14.
American Congress of Obstetricians and Gynecologists, Committee on Obstetric Practice. ACOG committee opinion: scheduled Cesarean delivery and the prevention of vertical transmission of HIV infection. Int J Gynaecol Obstet. 2001;73(3):279–81. [PubMed: 11424912]
15.
Read JS. American Academy of Pediatrics Committee on Pediatric AIDS. Human milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States. Pediatrics. 2003;112(5):1196–205. [PubMed: 14595069]
16.
Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet. 1992;340(8819):585–8. [PubMed: 1355163]
17.
Nduati R. Breastfeeding and HIV-1 infection: a review of current literature. In: Koletzko B, Michaelsen KF, Hernell O, editors. Short and Long Term Effects of Breast Feeding on Child Health. New York: Kluwer Academic; 2002. pp. 201–10.
18.
Office of Inspector General. Reducing Obstetrician Barriers to Offering HIV Testing. Washington, DC: Department of Health and Human Services; 2002. [9 November 2012]. Accessed at https://oig​.hhs.gov/oei​/reports/oei-05-01-00260.pdf on.
19.
Breastfeeding and HIV International Transmission Study Group. Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris DR, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis. 2004;189(12):2154–66. [PubMed: 15181561]
20.
Mofenson LM. Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther. 2010;15(4):537–53. [PubMed: 20587847]
21.
Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: pathogenesis, mechanisms and pathways. Clin Perinatol. 2010;37(4):721–37. [PubMed: 21078446]
22.
French R, Brocklehurst P. The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998;105(8):827–35. [PubMed: 9746374]
23.
Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, et al. The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol. 2003;189(2):552–9. [PubMed: 14520233]
24.
HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Rockville, MD: Department of Health and Human Services; 2012. [9 November 2012]. Accessed at http://aidsinfo​.nih.gov​/guidelines/html/3​/perinatal-guidelines/0/ on.
25.
Centers for Disease Control. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. JAMA. 1989;262(24):3395–7. [PubMed: 2685380]
26.
Celum CL, Coombs RW, Jones M, Murphy V, Fisher L, Grant C, et al. Risk factors for repeatedly reactive HIV-1 EIA and indeterminate Western blots: a population-based case-control study. Arch Intern Med. 1994;154(10):1129–37. [PubMed: 7910452]
27.
Branson BM. The future of HIV testing. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S102–5. [PubMed: 21406978]
28.
Bulterys M, Jamieson DJ, O’Sullivan MJ, Cohen MH, Maupin R, Nesheim S, et al. Mother-Infant Rapid Intervention at Delivery (MIRIAD) Study Group. Rapid HIV-1 testing during labor: a multicenter study. JAMA. 2004;292(2):219–23. [PubMed: 15249571]
29.
Centers for Disease Control and Prevention. Rapid HIV-1 Antibody Testing During Labor and Delivery for Women of Unknown HIV Status: A Practical Guide and Model Protocol. Atlanta: Centers for Disease Control and Prevention; 2004. [9 November 2012]. Accessed at http://www​.cdc.gov/hiv​/topics/testing/resources​/guidelines/rt-labor&delivery.htm on.
30.
Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006;8(2):125–31. [PubMed: 16524549]
31.
Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17. [PubMed: 16988643]
32.
American College of Obstetrics and Gynecology Committee on Obstetric Practice. ACOG committee opinion no. 418: prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol. 2008;112(3):739–42. [PubMed: 18757690]
33.
American Academy of Family Physicians. Human Immunodeficiency Virus (HIV). Leawood, KS: American Academy of Family Physicians; 2005. [9 November 2012]. Accessed at http://www​.aafp.org/online​/en/home/clinical/exam/hiv.html on.
34.
American Academy of Pediatrics Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics. 2008;122(5):1127–34. [PubMed: 18977995]
35.
American Academy of Pediatrics. Policy statement: AAP publications reaffirmed and retired. Pediatrics. 2011;128(3):e748.
36.
Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK. Clinical Efficacy Assessment Subcommittee, American College of Physicians. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150(2):125–31. [PubMed: 19047022]
37.
Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Methods Work Group, Third US Preventive Services Task Force. Current methods of the third U.S. Preventive Services Task Force. Am J Prev Med. 2001;20(3 Suppl):21–35. [PubMed: 11306229]
38.
Sansom SL, Jamieson DJ, Farnham PG, Bulterys M, Fowler MG. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol. 2003;102(4):782–90. [PubMed: 14551009]
39.
Jamieson DJ, Cohen MH, Maupin R, Nesheim S, Danner SP, Lampe MA, et al. Rapid human immunodeficiency virus-1 testing on labor and delivery in 17 US hospitals: the MIRIAD experience. Am J Obstet Gynecol. 2007;197(3 Suppl):S72–82. [PubMed: 17825653]
40.
Tung CS, Sangi-Haghpeykar H, Levison J. Rapid versus standard testing for prenatal HIV screening in a predominantly Hispanic population. J Perinatol. 2010;30(1):30–2. [PubMed: 19741654]
41.
Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331(18):1173–80. [PubMed: 7935654]
42.
Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Women and Infants’ Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29(5):484–94. [PubMed: 11981365]
43.
Italian Register for Human Immunodeficiency Virus Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med. 2002;156(9):915–21. [PubMed: 12197800]
44.
European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(3):458–65. [PubMed: 15668871]
45.
Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Bénifla JL, Burgard M, et al. Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285(16):2083–93. [PubMed: 11311097]
46.
Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. Perinatal HIV Prevention Trial (Thailand) Investigators. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;343(14):982–91. [PubMed: 11018164]
47.
Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Bangkok Collaborative Perinatal HIV Transmission Study Group. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 1999;353(9155):773–80. [PubMed: 10459957]
48.
Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359(9313):1178–86. [PubMed: 11955535]
49.
Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet. 1999;353(9155):781–5. [PubMed: 10459958]
50.
Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. DITRAME Study Group. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet. 1999;353(9155):786–92. [PubMed: 10459959]
51.
Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187(5):725–35. [PubMed: 12599045]
52.
Taha TE, Kumwenda NI, Gibbons A, Broadhead RL, Fiscus S, Lema V, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet. 2003;362(9391):1171–7. [PubMed: 14568737]
53.
Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362(9387):859–68. [PubMed: 13678973]
54.
Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA. 2004;292(2):202–9. [PubMed: 15249569]
55.
Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795–802. [PubMed: 10485720]
56.
Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS. 2008;22(8):973–81. [PubMed: 18453857]
57.
Harris NS, Fowler MG, Sansom SL, Ruffo N, Lampe MA. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999–2001. Am J Obstet Gynecol. 2007;197(3 Suppl):S33–41. [PubMed: 17825649]
58.
Garcia-Tejedor A, Maiques V, Perales A, Lopez-Aldeguer J. Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical HIV transmission. Acta Obstet Gynecol Scand. 2009;88(8):882–7. [PubMed: 19557554]
59.
Tariq S, Townsend CL, Cortina-Borja M, Duong T, Elford J, Thorne C, et al. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000–2009. J Acquir Immune Defic Syndr. 2011;57(4):326–33. [PMC free article: PMC3319104] [PubMed: 21499113]
60.
Kesho Bora Study Group. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171–80. [PubMed: 21237718]
61.
Chi BH, Chintu N, Cantrell RA, Kankasa C, Kruse G, Mbewe F, et al. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. J Acquir Immune Defic Syndr. 2008;48(2):220–3. [PubMed: 18520682]
62.
Gray G, Violari A, McIntyre J, Jivkov B, Schnittman S, Reynolds L, et al. Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants. J Acquir Immune Defic Syndr. 2006;42(2):169–76. [PubMed: 16639342]
63.
Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362(24):2282–94. [PMC free article: PMC2999916] [PubMed: 20554983]
64.
Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006;20(9):1281–8. [PubMed: 16816557]
65.
Thistle P, Spitzer RF, Glazier RH, Pilon R, Arbess G, Simor A, et al. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. Clinic Infect Dis. 2007;44(1):111–9. [PubMed: 17143826]
66.
Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, Chintu N, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet. 2007;370(9600):1698–705. [PubMed: 17997151]
67.
Kesho Bora Study Group. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. J Acquir Immune Defic Syndr. 2010;54(5):533–41. [PubMed: 20543706]
68.
Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, Fowler MG, et al. Pediatrics AIDS Clinical Trials Group 288 Protocol Team. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr. 2003;32(2):170–81. [PubMed: 12571527]
69.
Watts DH, Lambert J, Stiehm ER, Harris DR, Bethel J, Mofenson L, et al. PACTG 185 Study Team. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr. 2003;33(5):585–93. [PubMed: 12902802]
70.
Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863–70. [PubMed: 12063370]
71.
European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001;15(6):761–70. [PubMed: 11371691]
72.
Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204(4):506–14. [PMC free article: PMC3144169] [PubMed: 21791651]
73.
Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, et al. ANRS French Perinatal Cohort. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS. 2009;23(10):1235–43. [PubMed: 19424054]
74.
Carceller A, Ferreira E, Alloul S, Lapointe N. Lack of effect on prematurity, birth weight, and infant growth from exposure to protease inhibitors in utero and after birth. Pharmacotherapy. 2009;29(11):1289–96. [PubMed: 19857146]
75.
Cotter AM, Garcia AG, Duthely ML, Luke B, O’Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193(9):1195–201. [PubMed: 16586354]
76.
El Beitune P, Duarte G, Machado AA, Quintana SM, Figueiró-Filho EA, Abduch R. Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates. Clinics (Sao Paulo) 2005;60(3):207–12. [PubMed: 15962081]
77.
Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al. Multicenter Interdisciplinary Study Group Germany/Austria. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med. 2008;9(1):6–13. [PubMed: 18199167]
78.
Morris AB, Dobles AR, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr. 2005;40(1):30–3. [PubMed: 16123678]
79.
Paul ME, Chantry CJ, Read JS, Frederick MM, Lu M, Pitt J, et al. Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: the Women and Infants Transmission Study. Pediatr Infect Dis. J. 2005;24(1):46–56. [PubMed: 15665710]
80.
Rudin C, Spaenhauer A, Keiser O, Rickenbach M, Kind C, Aebi-Popp K, et al. Swiss Mother & Child HIV Cohort Study (MoCHiV). Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med. 2011;12(4):228–35. [PubMed: 20726902]
81.
Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989–2004. Pediatrics. 2007;119(4):900–6. [PubMed: 17353299]
82.
Townsend CL, Cortina-Borja M, Peckham C, Tookey P. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21:1019–26. [PubMed: 17457096]
83.
Poirier MC. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr. 2003;33(2):175–83. [PubMed: 12794551]
84.
Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to combivir. AIDS. 2004;18:1013–21. [PubMed: 15096804]
85.
Alimente A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J. 2003;22(9):782–8. [PubMed: 14506368]
86.
Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000;25(3):261–8. [PubMed: 11115957]
87.
Lindegren ML, Rhodes P, Gordon L, Fleming P. Perinatal Safety Review Working Group; State and Local Health Department HIV/AIDS Surveillance Programs. Drug safety during pregnancy and in infants: lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci. 2000;918(1):222–35. [PubMed: 11131709]
88.
Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, Lampe M, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women: retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci. 2000;918(1):212–21. [PubMed: 11131707]
89.
Dominguez K, Bertolli J, Fowler M, Peters V, Ortiz I, Melville S, et al. PSD Consortium. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children ≤5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA. Ann N Y Acad Sci. 2000;918(1):236–46. [PubMed: 11131710]
90.
Aldrovandi GM, Chu C, Shearer WT, Li D, Walter J, Thompson B, et al. Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics. 2009;124(6):e1189–97. [PMC free article: PMC2904486] [PubMed: 19933732]
91.
Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21(8):929–38. [PubMed: 17457086]
92.
Côté HC, Raboud J, Bitnun A, Alimenti A, Money DM, Maan E, et al. Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants. J Infect Dis. 2008;198(6):851–9. [PubMed: 18684095]
93.
Patel D, Thorne C, Fiore S, Newell ML. European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr. 2005;40(1):116–8. [PubMed: 16123696]
94.
Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. AIDS. 2009;23(4):519–24. [PubMed: 19165088]
95.
Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofenson L, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med. 2011;39(2):163–70. [PMC free article: PMC3068472] [PubMed: 21142844]
96.
Alimenti A, Forbes JC, Oberlander TF, Money DM, Grunau RE, Papsdorf MP, et al. A prospective controlled study of neurodevelopment of HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics. 2006;118(4):e1139–45. [PubMed: 16940166]
97.
Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM. PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 2010;125(2):e250–60. [PMC free article: PMC2951128] [PubMed: 20083530]
98.
Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med. 2000;343(11):759–66. [PubMed: 10984563]
99.
Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, Orav EJ, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children Cohort Study) J Am Coll Cardiol. 2011;57(1):76–85. [PMC free article: PMC3243620] [PubMed: 21185505]
100.
Bunders MJ, Bekker V, Scherpbier HJ, Boer K, Godfried M, Kuijpers TW. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr. 2005;94(11):1571–7. [PubMed: 16303696]
101.
Mussi-Pinhata MM, Rego MA, Freimanis L, Kakehasi FM, Machado DM, Cardoso EM, et al. NISDI Perinatal Protocol Study Group. Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study. Pediatr Infect Dis J. 2007;26(11):1032–7. [PubMed: 17984811]
102.
Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, et al. Women and Infants Transmission Study. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the Women and Infants Transmission Study. J Infect Dis. 2006;194(8):1089–97. [PubMed: 16991083]
103.
Benhammou V, Warszawski J, Bellec S, Doz F, André N, Lacour B, et al. ANRS-Enquête Périnatale Française. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS. 2008;22(16):2165–77. [PubMed: 18832880]
104.
Brocklehurst P. Interventions for reducing the risk of mother-to-child transmision of HIV infection. Cochrane Database Syst Rev. 2002;1:CD000102. [PubMed: 11869564]
105.
Watts DH, Balasubramanian R, Maupin RT Jr, Delke I, Dorenbaum A, Fiore S, et al. PACTG 316 Study Team. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol. 2004;190(2):506–16. [PubMed: 14981398]
106.
Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, et al. PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36(3):772–6. [PubMed: 15213559]
107.
Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351(3):217–28. [PubMed: 15247338]
108.
Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Women and Infants Transmission Study. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38(4):449–73. [PubMed: 15764963]
109.
Marti C, Peña JM, Bates I, Madero R, de José I, Pallardo LF, et al. Obstetric and perinatal complications in HIV-infected women: analysis of a cohort of 167 pregnancies between 1997 and 2003. Acta Obstet Gynecol Scand. 2007;86(4):409–15. [PubMed: 17486461]
110.
Pinnetti C, Barconcelli S, Villani P, Fantoni M, Tozzi V, De Luca A, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother. 2010;65(9):2050–2. [PubMed: 20630894]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.3M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...